Pfizer today announced that it has signed a voluntary licensing agreement to expand production of its new COVID-19 treatment, Paxlovid, for low- and middle-income countries, which follows a similar announcement from Merck for molnupiravir.Also today, Pfizer announced that it has applied for emergency use authorization from the US Food and Drug Administration (FDA) for Paxlovid.
The Biden administration plans to buy 10 million treatment courses of the Pfizer drug, sources told NBC News.Deal would ease access for 95 countriesIn its licensing announcement, Pfizer said it signed an agreement with the Medicines Patent Pool (MPP), a United Nations-based group, enabling MPP to boost international production by granting sublicenses to generic